These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15163266)

  • 1. Dosing differences between valproic acid concentrate and divalproex sodium: a case report.
    Coffey G; Botts S; de Leon J
    J Clin Psychiatry; 2004 May; 65(5):724-5. PubMed ID: 15163266
    [No Abstract]   [Full Text] [Related]  

  • 2. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
    Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
    J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism.
    Riesselman A; Strobl B; Cooley AT; de Leon J
    J Clin Psychopharmacol; 2013 Dec; 33(6):812-4. PubMed ID: 24113673
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibuprofen May Increase Pharmacological Action of Valproate by Displacing It From Plasma Proteins: A Case Report.
    Lana F; Martí-Bonany J; de Leon J
    Am J Psychiatry; 2016 Sep; 173(9):941-2. PubMed ID: 27581700
    [No Abstract]   [Full Text] [Related]  

  • 7. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report.
    Begum M
    Aust N Z J Psychiatry; 2005 Mar; 39(3):202. PubMed ID: 15701074
    [No Abstract]   [Full Text] [Related]  

  • 8. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets.
    Dutta S; Reed RC
    J Clin Pharmacol; 2006 Aug; 46(8):952-7. PubMed ID: 16855080
    [No Abstract]   [Full Text] [Related]  

  • 10. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium.
    Dutta S; Reed RC
    Am J Health Syst Pharm; 2006 May; 63(10):904-6. PubMed ID: 16675645
    [No Abstract]   [Full Text] [Related]  

  • 12. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
    Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA
    Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Pharmacokinetic interaction between clozapine and mirtazapine.
    Lo Presti C; Laguin S; Bambina E; Arlotto E; Aghazarian V; Guise-Honore S
    Encephale; 2019 Sep; 45(4):363-364. PubMed ID: 30879778
    [No Abstract]   [Full Text] [Related]  

  • 15. Divalproex-ER pharmacokinetics in older children and adolescents.
    Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
    Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which oral valproic acid formulation is best for my patient?
    Knox JE; Freeland KN
    JAAPA; 2015 Jan; 28(1):21-3. PubMed ID: 25522023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the bioequivalence of generic versus branded clozapine.
    Ereshefsky L; Glazer WM
    J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845
    [No Abstract]   [Full Text] [Related]  

  • 18. Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia.
    Tornatore FL
    J Clin Psychiatry; 2005 Nov; 66(11):1493-4; author reply 1494. PubMed ID: 16420093
    [No Abstract]   [Full Text] [Related]  

  • 19. Clozapine. A novel antipsychotic agent.
    Baldessarini RJ; Frankenburg FR
    N Engl J Med; 1991 Mar; 324(11):746-54. PubMed ID: 1671793
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible role of divalproex sodium in sedation induced by antipsychotic medications.
    Berigan TR
    J Clin Psychiatry; 2004 Jan; 65(1):133. PubMed ID: 14974492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.